Fig. 4

Intradermal administration of agomir-125a-5p ameliorates the pathological phenotype of IMQ-induced psoriasis-like mice. a Schematic diagram of the intradermal administration of agomir-125a-5p (4 nmol/day) and agomir-NC (4 nmol/day) on days 0, 1, 2, 3, and 4 after application of IMQ in mice (BALB/c). The mice in each group were sacrificed on day 6. b Phenotypic presentation of back skin lesions of each group on day 0 and day 6. c Representative H&E staining of back lesions of each group on day 6 (×200) (upper panels). Representative immunohistochemistry sections of ki67 and CD3 staining (brown) of the back skin lesions (middle and bottom panels). Scale bar: 50 μm. d Improved PASI scoring of skin lesions, including erythema, scaling, thickness, and total PASI scores. As in thickness, there was no standard deviation on day 5 and day 6 since the scores remained at 4. Data are representative of at least two independent experiments (mean ± SEM). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Two-tailed unpaired Student’s t-test (d). miR, microRNA; agomir-NC, negative control agomir; Con, control; IMQ, imiquimod; H&E staining, Hematoxylin and Eosin staining; PASI, Psoriasis Area and Severity Index